Table 1

Characteristics of the rheumatoid arthritis patient cohorts
Characteristics All RA patients Longitudinal etanercept study
(N= 75) (N= 16)
Median age, years (range) 57.0 (23 to 83) 56.0 (41 to 66)
Female/male (n) 55/20 10/6
Median disease duration, years (range) 7.0 (1 to 57) 2 (1 to 13)
RF-positive (%) 77.0 68.8
Anti-CCP-positive (%) 75.8 93.8
Median CRP, mg/dl (range) 3.53 (0 to 113) 4.40 (0.5 to 21.1)
DMARDs (n)
  Methotrexate 42 13
  Azathioprine 1 0
  Leflunomide 4 1
  Anti-TNF 7 0
  Anti-TNF + MTX 2 0
  Abatacept 1 0
  Hydroxychloroquine + MTX 1 1
  Cyclosporin A 1 0
  Cyclosporin A + MTX 1 0
  Tocilizumab 1 0
  Rituximab 1 0
  Without 13 1

aCCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor.

Krasselt et al.

Krasselt et al. Arthritis Research & Therapy 2013 15:R139   doi:10.1186/ar4321

Open Data